Form 4: Myriad Genetics SVP Margaret Ancona Reports Changes in Beneficial Ownership

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports acquisition and disposal of common stock and restricted stock units.

Summary

• On March 13, 2025, Margaret Ancona acquired 54,124 shares of common stock at $0, resulting in a total of 136,295 shares beneficially owned.
• On March 14 and 15, 2025, Ancona disposed of 3,417 and 1,572 shares respectively at a price of $10.07 to cover tax obligations related to vesting restricted stock units, resulting in 132,878 and 131,306 shares beneficially owned respectively.
• The acquired shares consist of time-based restricted stock units that vest in three equal annual installments starting on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing represents routine transactions related to executive compensation. The acquisition of shares is a positive sign, but the disposal is simply to cover tax obligations.

Positives

• The acquisition of restricted stock units indicates a continued alignment of the executive's interests with the company's long-term performance.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates